<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489476</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-104-201</org_study_id>
    <nct_id>NCT00489476</nct_id>
  </id_info>
  <brief_title>Staccato Loxapine in Migraine (in Clinic)</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of StaccatoÂ® Loxapine for Inhalation in Patients With Migraine Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to assess the efficacy and safety of Staccato Loxapine in
      patients with migraine headache with or without aura in a clinical setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll male and female patients with migraine headache with or without aura.
      The study will randomize ~160 patients, 1:1:1:1 to receive one of the following treatments:
      1.25 mg Staccato Loxapine; 2.5 mg Staccato Loxapine; 5 mg Staccato Loxapine; Staccato
      Placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain-relief Response (Pain Severity of NONE or MILD) at 2 Hours</measure>
    <time_frame>Baseline and 2 h post-dose</time_frame>
    <description>The primary efficacy endpoint was Pain-relief response as defined by the International Headache Society (Pain-IHS) as a pain severity of NONE or MILD.
Intent to treat (ITT) with last observation carried forward (LOCF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain-free at 2 Hours</measure>
    <time_frame>Baseline and 2 h post-dose</time_frame>
    <description>Pain-free (Pain-IHS) at the 2 hour time point</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Responders, Sustained Freedom From Pain</measure>
    <time_frame>Baseline through 24 h post-dose</time_frame>
    <description>The percentages of patients with sustained freedom from pain (pain-free at 2 hours after dosing with no rescue medication and no recurrence of headache from 2 to 24 hours)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>1.25 mg Staccato Loxapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.25 mg ADASUVE, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5 mg Staccato Loxapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg ADASUVE, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg Staccato Loxapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg ADASUVE, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Staccato Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Staccato Placebo, 0 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Staccato Loxapine</intervention_name>
    <arm_group_label>1.25 mg Staccato Loxapine</arm_group_label>
    <arm_group_label>2.5 mg Staccato Loxapine</arm_group_label>
    <arm_group_label>5 mg Staccato Loxapine</arm_group_label>
    <other_name>ADASUVE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Staccato Placebo</intervention_name>
    <description>Placebo aerosol inhalation (0mg)</description>
    <arm_group_label>Staccato Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients between the ages of 18 to 65 years, inclusive.

          2. Patients who have migraine headache with or without aura (diagnosis according to
             International Headache Society guidelines) for at least 6 months.

          3. Patients who have a history of migraine and have had at least 3 migraine attacks in
             the last 3 month period (but not more than 8 migraine attacks in the last month).

          4. Patients who have been pain free for at least 48 hours since the end of their last
             migraine attack.

          5. Patients who have not taken any acute migraine or pain medication within 48 hours
             prior to dosing (including OTC products).

          6. Patients who have a pain rating of Moderate or Severe (on a None-Mild- Moderate-Severe
             Scale) prior to dosing.

          7. Patients who speak, read, and understand English and are willing and able to provide
             written informed consent on an IRB approved form prior to the initiation of any study
             procedures.

          8. Patients who are willing and able to comply with the study schedule and requirements,
             are willing and able to travel to the Clinical Research Unit (CRU) for treatment and
             stay at the CRU for approximately a 4-6 hour period, and agree to return to the clinic
             within 5 working days of use of the investigational treatment.

          9. Patients who are in good general health prior to study participation as determined by
             a detailed medical history, physical examination, 12-lead ECG, blood chemistry
             profile, hematology, urinalysis, and in the opinion of the Principal Investigator.

         10. Female participants (if of child-bearing potential and sexually active) and male
             participants (if sexually active with a partner of child-bearing potential) who agree
             to use a medically acceptable and effective birth control method throughout the study
             and for one week following the end of the study. Medically acceptable methods of
             contraception that may be used by the participant and/or his/her partner include
             abstinence, birth control pills or patches, diaphragm with spermicide, intrauterine
             device (IUD), condom with foam or spermicide, vaginal spermicidal suppository,
             surgical sterilization, and progestin implant or injection. Prohibited methods
             include: the rhythm method, withdrawal, condoms alone, or diaphragm alone.

        Exclusion Criteria:

          1. Patients who are currently taking antipsychotics, tricyclic antidepressants,
             valproate, barbiturates, benzodiazepines, or lithium must be excluded.

          2. Patients with a history of contraindications to anticholinergics (bowel obstruction,
             urinary retention, acute glaucoma) must be excluded.

          3. Patients with a history of allergy or intolerance to dibenzoxazepines (loxapine and
             amoxapine) must be excluded.

          4. Patients with a history of extra-pyramidal disorders, movement disorders including
             Parkinson's disease, and patients with a history of neuroleptic malignant syndrome
             must be excluded.

          5. Female patients who have a positive pregnancy test at screening or during
             randomization visit, or are breastfeeding must be excluded.

          6. Patients who have a history within the past year of drug or alcohol dependence or
             abuse as defined by DSM-4 must be excluded.

          7. Patients who have a history of syncope, unstable angina, myocardial infarction (within
             6 months), congestive heart failure, transient ischemic attack, or pheochromocytoma
             must be excluded.

          8. Patients who have a history of a major neurological disorder other than migraine
             (seizure disorder, subarachnoid bleeding, stroke, brain tumor) must be excluded.

          9. Patients who have any other disease(s), by history, physical examination, or
             laboratory abnormalities (ALT or AST &gt; 2-fold the upper limit of normal, Bilirubin &gt;
             1.5 mg/dL, or creatinine &gt; 1.8 mg/dL) or that in the investigator's opinion, would
             present undue risk to the patient or may confound the interpretation of study results
             must be excluded.

         10. Patients who have a history of asthma or chronic obstructive lung disease should be
             excluded.

         11. Patients who have received an investigational drug within 30 days prior to the
             Screening Visit must be excluded.

         12. Patients who are considered by the investigator, for any reason, to be an unsuitable
             candidate for receiving loxapine, or unable to use the inhalation device, must be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egilius Spierings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MedVadis Research Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medvadis</name>
      <address>
        <city>Wellesley Hills</city>
        <state>Massachusetts</state>
        <zip>02481-2106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <results_first_submitted>March 13, 2017</results_first_submitted>
  <results_first_submitted_qc>March 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2017</results_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>StaccatoÂ® Loxapine, Migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loxapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Staccato Placebo</title>
          <description>Staccato Placebo, 0 mg
Staccato Placebo: Placebo aerosol inhalation (0mg)</description>
        </group>
        <group group_id="P2">
          <title>1.25 mg Staccato Loxapine</title>
          <description>1.25 mg ADASUVE, single dose
Staccato Loxapine</description>
        </group>
        <group group_id="P3">
          <title>2.5 mg Staccato Loxapine</title>
          <description>2.5 mg ADASUVE, single dose
Staccato Loxapine</description>
        </group>
        <group group_id="P4">
          <title>5 mg Staccato Loxapine</title>
          <description>5 mg ADASUVE, single dose
Staccato Loxapine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Staccato Placebo</title>
          <description>Staccato Placebo, 0 mg
Staccato Placebo: Placebo aerosol inhalation (0mg)</description>
        </group>
        <group group_id="B2">
          <title>1.25 mg Staccato Loxapine</title>
          <description>1.25 mg ADASUVE, single dose
Staccato Loxapine</description>
        </group>
        <group group_id="B3">
          <title>2.5 mg Staccato Loxapine</title>
          <description>2.5 mg ADASUVE, single dose
Staccato Loxapine</description>
        </group>
        <group group_id="B4">
          <title>5 mg Staccato Loxapine</title>
          <description>5 mg ADASUVE, single dose
Staccato Loxapine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="43"/>
            <count group_id="B5" value="168"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="168"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="10.94"/>
                    <measurement group_id="B2" value="41.7" spread="13.09"/>
                    <measurement group_id="B3" value="38.5" spread="11.89"/>
                    <measurement group_id="B4" value="42.3" spread="12.68"/>
                    <measurement group_id="B5" value="41.1" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain-relief Response (Pain Severity of NONE or MILD) at 2 Hours</title>
        <description>The primary efficacy endpoint was Pain-relief response as defined by the International Headache Society (Pain-IHS) as a pain severity of NONE or MILD.
Intent to treat (ITT) with last observation carried forward (LOCF)</description>
        <time_frame>Baseline and 2 h post-dose</time_frame>
        <population>ITT Population with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Staccato Placebo</title>
            <description>Staccato Placebo, 0 mg
Staccato Placebo: Placebo aerosol inhalation (0mg)</description>
          </group>
          <group group_id="O2">
            <title>1.25 mg Staccato Loxapine</title>
            <description>1.25 mg ADASUVE, single dose
Staccato Loxapine</description>
          </group>
          <group group_id="O3">
            <title>2.5 mg Staccato Loxapine</title>
            <description>2.5 mg ADASUVE, single dose
Staccato Loxapine</description>
          </group>
          <group group_id="O4">
            <title>5 mg Staccato Loxapine</title>
            <description>5 mg ADASUVE, single dose
Staccato Loxapine</description>
          </group>
        </group_list>
        <measure>
          <title>Pain-relief Response (Pain Severity of NONE or MILD) at 2 Hours</title>
          <description>The primary efficacy endpoint was Pain-relief response as defined by the International Headache Society (Pain-IHS) as a pain severity of NONE or MILD.
Intent to treat (ITT) with last observation carried forward (LOCF)</description>
          <population>ITT Population with LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0212</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0106</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain-free at 2 Hours</title>
        <description>Pain-free (Pain-IHS) at the 2 hour time point</description>
        <time_frame>Baseline and 2 h post-dose</time_frame>
        <population>ITT with LOCF Population</population>
        <group_list>
          <group group_id="O1">
            <title>Staccato Placebo</title>
            <description>Staccato Placebo, 0 mg
Staccato Placebo: Placebo aerosol inhalation (0mg)</description>
          </group>
          <group group_id="O2">
            <title>1.25 mg Staccato Loxapine</title>
            <description>1.25 mg ADASUVE, single dose
Staccato Loxapine</description>
          </group>
          <group group_id="O3">
            <title>2.5 mg Staccato Loxapine</title>
            <description>2.5 mg ADASUVE, single dose
Staccato Loxapine</description>
          </group>
          <group group_id="O4">
            <title>5 mg Staccato Loxapine</title>
            <description>5 mg ADASUVE, single dose
Staccato Loxapine</description>
          </group>
        </group_list>
        <measure>
          <title>Pain-free at 2 Hours</title>
          <description>Pain-free (Pain-IHS) at the 2 hour time point</description>
          <population>ITT with LOCF Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0123</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0228</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Responders, Sustained Freedom From Pain</title>
        <description>The percentages of patients with sustained freedom from pain (pain-free at 2 hours after dosing with no rescue medication and no recurrence of headache from 2 to 24 hours)</description>
        <time_frame>Baseline through 24 h post-dose</time_frame>
        <population>ITT with LOCF Population</population>
        <group_list>
          <group group_id="O1">
            <title>Staccato Placebo</title>
            <description>Staccato Placebo, 0 mg
Staccato Placebo: Placebo aerosol inhalation (0mg)</description>
          </group>
          <group group_id="O2">
            <title>1.25 mg Staccato Loxapine</title>
            <description>1.25 mg ADASUVE, single dose
Staccato Loxapine</description>
          </group>
          <group group_id="O3">
            <title>2.5 mg Staccato Loxapine</title>
            <description>2.5 mg ADASUVE, single dose
Staccato Loxapine</description>
          </group>
          <group group_id="O4">
            <title>5 mg Staccato Loxapine</title>
            <description>5 mg ADASUVE, single dose
Staccato Loxapine</description>
          </group>
        </group_list>
        <measure>
          <title>Responders, Sustained Freedom From Pain</title>
          <description>The percentages of patients with sustained freedom from pain (pain-free at 2 hours after dosing with no rescue medication and no recurrence of headache from 2 to 24 hours)</description>
          <population>ITT with LOCF Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0409</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment</time_frame>
      <desc>Adverse events (AEs) were assessed at 9 pre-specified time points as well as whenever spontaneously reported by the subjects or study staff</desc>
      <group_list>
        <group group_id="E1">
          <title>Staccato Placebo</title>
          <description>Staccato Placebo, 0 mg
Staccato Placebo: Placebo aerosol inhalation (0mg)</description>
        </group>
        <group group_id="E2">
          <title>1.25 mg Staccato Loxapine</title>
          <description>1.25 mg ADASUVE, single dose
Staccato Loxapine</description>
        </group>
        <group group_id="E3">
          <title>2.5 mg Staccato Loxapine</title>
          <description>2.5 mg ADASUVE, single dose
Staccato Loxapine</description>
        </group>
        <group group_id="E4">
          <title>5 mg Staccato Loxapine</title>
          <description>5 mg ADASUVE, single dose
Staccato Loxapine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia Oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Oral Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in Attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngeal Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive VP, Research &amp; Development, Regulatory &amp; Quality</name_or_title>
      <organization>Alexza Pharmaceuticals, Inc</organization>
      <phone>650.944.7071</phone>
      <email>ClinicalTrialsInfo@alexza.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

